ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 16 of 61
JMBS 2018, 3(5): 81–85
Clinical Medicine

The Application of Lavamax in Treatment of Chronic Recurrent Urogenital Herpes Viral Infection

Gomozova E. A., Grona N. V., Gul'mamedova M. F., Zhdanyuk Yu. I., Kozinskaya I. A., Suprun A. A., Taktashov G. S.

The recurrence of chronic viral infections, which are caused by Herpes group, happens due to a decrease of common immunoreactivity, especially of the cell part of immune system. Cellular immunodeficiency is a pathogenetic basis for the development of chronic viral infections. Thus, their successful treatment is possible only when antiviral and immunotropic therapies are combined. Optimal correction of cellular part of immune system is the required condition for effective treatment of herpes viral infections, including those which are caused by type II virus. The purpose of the study was to learn the efficiency of drug Lavomax application in treatment of patients with chronic recurrent urogenital herpes viral infection caused by type II herpes virus. Material and methods. 56 patients with chronic recurrent urogenital herpes underwent supervision and examination. Among them there were 30 women (53.6%) and 26 men (46.4%) aged from 21 to 50, 31 (55.4%) of the above mentioned were younger than 30 years old. The duration of recurrence in 23.2% of patients was 3-5 days, in 46.4% of patients – 5-10 days, in 30.4% – 10 days and more. During clinical study of Lavomax efficiency and tolerance of the patients were divided in 2 groups. The first group was represented by 30 patients (16 women and 14 men), who got combined therapy – Lavomax with antiviral drug Valtrex. 3 women and 3 men had mild clinical course, 8 women and 7 men had clinical course of middle severity, 5 and 4 respectively – severe clinical course. The second group (the group of comparison) was represented by 26 patients (14 women and 12 men), who got Valtrex monotherapy. 3 men and 5 women had mild clinical course, 5 men and 6 women – clinical course of middle severity, 4 and 3 – severe clinical course. The results of treatment were assessed in 30 days after its start. Results and discussion. During results evaluation it was estimated that application of Lavomax in complex therapy with antiviral drug Valtrex provided significant decrease of disease symptoms duration and decrease of recurrence numbers after the end of treatment during half a year of observation. The study of cell immunity showed the presence of T-cell immunodeficiency in examined patients, which was cured in the group of patients, who got Lavomax, the application of Valtrex monotherapy didn’t provide such an effect. The study of interferon status also showed its normalization in group of patients, who got Lavomax, in group of comparison the interferon production dynamics was statistically unreliable. Conclusions. The application of Lavomax in complex therapy of patients lead to the essential decrease of disease manifestation with the significant (P<0.05) decrease of recurrence frequency after carried-out 30-days’ therapy course. This effect was obtained on the background of serious improvement (P<0.05) of cellular immunity indices and interferon status (P<0.001). The obtained results, which showed the decrease of recurrence number in case of addition of Lavomax in therapy complex, substantiate the need of its application in treatment and prophylactic schemes in patients suffering from this disease.

Keywords: herpes viral infection, immunodeficiency, interferon, treatment, Lavomax

Full text: PDF (Rus) 198K

  1. Ershov FY. Antygerpetyky. Rossyyskyy zhurnal kozhnykh y venerycheskykh bolezney (prylozhenye «Gerpes»). 2006; 1: 5–11. [Russian]
  2. Karymova YM. Gerpesvyrusnaya ynfektsyya. Dyagnostyka, klyny¬ka, lechenye. M., 2004. 120 s. [Russian]
  3. Khaldyn AA, Komratova ON, Kyselev AV. Sovremennye voz¬mozhnosty y perspektyvy vtorychnoy profylaktyky prostogo gerpesa ynterferonogenamy. Rossyyskyy zhurnal kozhnykh y venerycheskykh bo¬lezney (prylozhenye «Gerpes»). 2006; 2: 44–8. [Russian]
  4. Patel P, Kennedy OJ, Clarke E, Geretti A, Nilsen A, Lautenschlager S, Green J, Donders G, van der Meijden W, Gomberg M, Moi H, Foley E. 2017 European guidelines for the management of genital herpes. International Journal of STD & AIDS. 2017; 28(14): 1366–79.
  5. Sauerbrei A. Optimal management of genital herpes: current perspectives. Infect Drug Resist. 2016; 9: 129–41. doi: 10.2147/IDR.S96164
  6. Schiffer JT, Corey L. New Concepts in Understanding Genital Herpes. Curr Infect Dis Rep. 2009 Nov; 11(6): 457–64.
  7. Wald A, Timmler B, Magaret A, Warren T, Tyring S, Johnston C, Fife K, Selke S, et al. Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences: A Randomized Clinical Trial. JAMA. 2016; 316: 2495-503.
  8. Workowski KA, Bolan GA; CDC. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015; 64: 1-137.